Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Alexandra Lindsey Djomkam Zune, Charles Ochieng’ Olwal, Theodore Beyeme Sala, Lily Paemka
Abstract
GENERAL COMMENTARY article Front. Oncol., 19 August 2020Sec. Molecular and Cellular Oncology Volume 10 - 2020 | https://doi.org/10.3389/fonc.2020.01448
Topics & Concepts
TMPRSS2Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakProteaseVirologyProtease inhibitor (pharmacology)MedicineBetacoronavirusCancer researchBiologyVirusEnzymeInternal medicineViral loadBiochemistryOutbreakInfectious disease (medical specialty)Antiretroviral therapyDiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesCOVID-19 Impact on Reproduction